WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage…
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company…
U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory EnvironmentGLEN ALLEN, Va.,…
These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion…
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE)…
The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help…
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetugREDWOOD CITY, Calif., Aug. 20, 2025…
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James…
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to EnrollCAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE…
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is…